FDAAPP / ANNUAL
Important information: If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
Before Jan 1, 2027
Resolves Yes if If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
Note: this event is directional.
Contracts settle at $1.00 if the outcome resolves Yes, and $0.00 if it resolves No. Positions can be closed any time before expiration at the prevailing market price.
Contracts settle at $1.00 if the outcome resolves Yes, and $0.00 if it resolves No. Positions can be closed any time before expiration at the prevailing market price.